Trial Profile

A Phase 1 / 2 Double-Blind, Randomized, Placebo Controlled Study of Safety, Tolerability and Potential Efficacy of AVOTRES Cell-Based Therapy (AVT001) in Patients With Type 1 Diabetes

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVT 001 (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors Avotres

Most Recent Events

10 Jul 2024 Status changed from active, no longer recruiting to completed.
06 Oct 2023 Results of one-year data of AVT001 to address this disruption in self-tolerance in type 1 diabetes, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
19 Jul 2023 According to a Avotres media release, the company will be ready to submit a clinical paper with Day 360 data to a top scientific journal shortly.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com